FDA approves first NPC survival treatment - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves first NPC survival treatment

  • By

  • Mouj Hijazi

  • November 18, 2026

  • 2 min

Share

Clinical Scorecard: FDA approves first NPC survival treatment

At a Glance

CategoryDetail
ConditionNiemann-Pick disease type C (NPC), an inherited lysosomal storage disorder associated with impaired intracellular cholesterol trafficking, lipid accumulation, and progressive neurological deterioration.
Key MechanismsAdrabetadex is a cyclodextrin-based therapy that binds cholesterol and helps move it out of lysosomes; the mechanism underlying its observed survival benefit has not been fully characterized.
Target PopulationAdults and children weighing at least 7 kg with NPC whose neurological symptoms began before age 6.
Care SettingIntrathecal treatment every 2 weeks, administered by or under the supervision of a clinician experienced in lumbar punctures, with audiological monitoring.

Key Highlights

  • FDA approval was supported by an integrated survival analysis of 36 adrabetadex-treated patients and matched external controls from a natural history study.
  • Median overall survival was 102 months with adrabetadex versus 59 months in the matched external-control group.
  • The analysis reported a 55% reduction in relative risk of death; deaths occurred in 12 of 36 treated patients versus an estimated 24 of 36 weighted external controls.
  • Longer survival was observed regardless of baseline miglustat use.
  • Adrabetadex carries a boxed warning for hearing impairment, including permanent hearing loss.

Guideline-Based Recommendations

Diagnosis

    Management

    • Administer adrabetadex intrathecally every 2 weeks by, or under the supervision of, a clinician experienced in lumbar punctures.
    • Use age-based starting doses of 100 to 400 mg; titrate upward based on tolerability and weight-dependent maximum doses of 600 or 900 mg.
    • Consider dose reductions for severe ataxia or fatigue.

    Monitoring & Follow-up

    • Perform a comprehensive audiological evaluation before treatment and repeat assessments during dose escalation.
    • Adjust subsequent doses based on hearing findings.

    Risks

    • The boxed warning identifies hearing impairment, including permanent hearing loss.
    • Common adverse reactions include ataxia, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough.

    Patient & Prescribing Data

    Adults and children weighing at least 7 kg with infantile-onset NPC, defined here as neurological symptoms beginning before age 6.

    The prescribing information specifies intrathecal dosing every 2 weeks. Starting doses range from 100 to 400 mg based on age, with upward titration based on tolerability and weight-dependent maximum doses of 600 or 900 mg.

    Clinical Best Practices

    • Ensure treatment is administered by or under the supervision of a clinician experienced in lumbar punctures.
    • Complete baseline audiological evaluation and repeat hearing assessments during dose escalation.
    • Base subsequent dose adjustments on hearing findings and consider dose reductions for severe ataxia or fatigue.

    Related Resources & Content

    Original Source(s)

    Related Content